X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Tavo works by optimizing cellular uptake of DNA-based IL-12 recruits and primes immune cancer-fighting cells in the tumor leading to systemic immune responses without systemic toxicity.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2021
Details:
KEYNOTE-695 is OncoSec's registration-directed Phase 2b trial evaluating TAVO, a DNA plasmid-based interleukin-12 (IL-12) + KEYTRUDA® (pembrolizumab) in patients with rigorously confirmed anti-PD-1 checkpoint resistant metastatic melanoma.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: TAVO
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 15, 2021
Details:
The CORVax12 vaccine approach combines the co-administration of OncoSec’s TAVO with a DNA-encodable version of the SARS-CoV-2 spike glycoprotein to boost the immunogenicity of the component developed by NIAID Vaccine Research Center scientists.
Lead Product(s): SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid
Therapeutic Area: Infections and Infectious Diseases Product Name: CORVax12
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institutes of Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2021
Details:
Through this agreement, Sirtex gains an option to non-exclusively co-promote the Company's lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sirtex Medical
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 19, 2021
Details:
The applications are directed to the use of OncoSec's interleukin-12 (IL-12)-based immunotherapy platform, including its lead product candidate TAVO™ delivered with the Company's proprietary intratumoral gene electrotransfer system for the treatment of cancer.
Lead Product(s): Tavokinogene Telseplasmid,Undisclosed
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
OncoSec will present new positive interim data from its KEYNOTE-695 registration-enabled Phase 2b clinical trial investigating TAVO™ in combination with KEYTRUDA® in patients with anti-PD-1 checkpoint refractory metastatic melanoma at 35th SITC Annual Meeting.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2020
Details:
CORVax12 is the first next-generation DNA vaccine candidate to deliver spike (S) protein from SARS-CoV-2 plus immune-stimulating interleukin-12 (IL-12) to elicit T-cell activation and drive robust humoral immunity.
Lead Product(s): SARS-CoV-2 spike protein plasmid DNA vaccine,Tavokinogene Telseplasmid
Therapeutic Area: Infections and Infectious Diseases Product Name: CORVax12
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Patent covers the use of intratumoral electroporation of DNA encoding interleukins to treat cancer and is significant because it is not specific to which type of immune-stimulatory interleukin can be used to treat a patient, nor is it limited to a particular type of cancer.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2020
Details:
Anti-PD-1 immune checkpoint therapies, such as OPDIVO®, are an established first-line treatment for advanced melanoma, and encouraging clinical data suggest that they have clinically meaningful activity in the neoadjuvant setting as well.
Lead Product(s): Tavokinogene Telseplasmid,Nivolumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 27, 2020
Details:
OncoSec Medical Incorporated presented new data further demonstrating the power of OncoSec's next-generation IL-12 plasmid (TAVOPLUS) therapeutic when combined with a T cell stimulator (TAVOPLUS-CD3) or an enhanced chemokine gradient (TAVOPLUS-CXCL9).
Lead Product(s): Tavokinogene Telseplasmid,Undisclosed
Therapeutic Area: Oncology Product Name: Tavo plus
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
Details:
Based upon tumor regression in the heavily pretreated Cohort 1 of the KEYNOTE-890 study, the Company plans to expand into earlier first-line treatment to investigate the combination of TAVO and Merck's KEYTRUDA plus chemotherapy in patients with mTNBC.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Tavo
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2020
Details:
The allowed European claims are directed to methods of treating cancer by delivering a plasmid encoding an agonist of GITR, CD137, CD134, CD40L, or CD27 in combination with a plasmid encoding an immunostimulatory cytokine to a tumor by intratumoral electroporation.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 27, 2020
Details:
OncoSec will present new pre-clinical data demonstrating the utility of OncoSec's next-generation product candidate, TAVOPLUS, and its electroporation gene delivery system as a promising approach for patients with melanoma and other solid tumors.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
OncoSec will supply CORVax12 and its investigational APOLLO electroporation device to Providence as part of this effort and does not anticipate any additional capital commitment at this time.
Lead Product(s): Tavokinogene Telseplasmid,SARS-CoV-2 spike proteins
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: OncoSec Immunotherapies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 06, 2020
Details:
High impact peer-reviewed medical journal highlights overall response rate of 35.7% and complete response of 17.9% with demonstrable abscopal responses when using TAVO as a monotherapy.
Lead Product(s): Tavokinogene Telseplasmid
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2020
Details:
OncoSec will use this cash to fund its ongoing TAVO clinical development programs this year, including pivotal KEYNOTE-695 study in checkpoint resistant metastatic melanoma.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The Australian Research and Development Tax Incentive
Deal Size: $1.7 million Upfront Cash: Undisclosed
Deal Type: Funding March 11, 2020
Details:
Sirtex will support and assist OncoSec with pre-marketing activities for TAVO™ and its visceral lesion applicator (VLA) in exchange for low single-digit royalties on those products.
Lead Product(s): Tavokinogene Telseplasmid,Pembrolizumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Sirtex Medical
Deal Size: $30.0 million Upfront Cash: $30.0 million
Deal Type: Partnership February 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
